Apellis Q3 Loss Wider Than Expected, Syfovre Drives Sales - Nasdaq
| MEIP Stock | USD 2.87 0.10 3.61% |
Slightly above 55% of MEI Pharma's retail investors are presently thinking to get in. The analysis of the overall investor sentiment regarding MEI Pharma suggests that some traders are interested. MEI Pharma's investing sentiment overview a quick insight into current market opportunities from investing in MEI Pharma. Many technical investors use MEI Pharma stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
MEI |
Apellis Q3 Loss Wider Than Expected, Syfovre Drives Sales Nasdaq
Read at news.google.com
 |
MEI Pharma Fundamental Analysis
We analyze MEI Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MEI Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MEI Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
MEI Pharma is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
MEI Pharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with MEI Pharma stock to make a market-neutral strategy. Peer analysis of MEI Pharma could also be used in its relative valuation, which is a method of valuing MEI Pharma by comparing valuation metrics with similar companies.
Peers
MEI Pharma Related Equities
| SPRO | Spero Therapeutics | 9.64 | ||||
| VINC | Vincerx Pharma | 7.14 | ||||
| ATXI | Avenue Therapeutics | 5.71 | ||||
| ZVSA | ZyVersa Therapeutics | 5.19 | ||||
| RNAZ | Transcode Therapeutics | 5.02 | ||||
| ABOS | Acumen Pharmaceuticals | 2.48 | ||||
| DAWN | Day One | 1.13 | ||||
| HOOK | Hookipa Pharma | 0.52 | ||||
| ASMB | Assembly Biosciences | 0.49 | ||||
| OCUL | Ocular Therapeutix | 0.50 | ||||
| ACHL | Achilles Therapeutics | 0.87 | ||||
| CTMX | CytomX Therapeutics | 1.18 | ||||
| INZY | Inozyme Pharma | 1.45 | ||||
| TERN | Terns Pharmaceuticals | 1.56 | ||||
| ZURA | Zura Bio | 1.67 | ||||
| TIL | Instil Bio | 2.10 | ||||
| KZR | Kezar Life | 2.37 | ||||
| REVB | Revelation Biosciences | 2.44 | ||||
| PHIO | Phio Pharmaceuticals | 4.81 |
Additional Tools for MEI Stock Analysis
When running MEI Pharma's price analysis, check to measure MEI Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MEI Pharma is operating at the current time. Most of MEI Pharma's value examination focuses on studying past and present price action to predict the probability of MEI Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MEI Pharma's price. Additionally, you may evaluate how the addition of MEI Pharma to your portfolios can decrease your overall portfolio volatility.